Vanguard Group Inc Indaptus Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 256,265 shares of INDP stock, worth $269,078. This represents 0.0% of its overall portfolio holdings.
Number of Shares
256,265
Previous 256,265
-0.0%
Holding current value
$269,078
Previous $543,000
41.62%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding INDP
# of Institutions
19Shares Held
605KCall Options Held
0Put Options Held
0-
Investment House LLC Las Vegas, NV100KShares$104,9740.01% of portfolio
-
Geode Capital Management, LLC Boston, MA73.1KShares$76,7850.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$47,6020.01% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$46,2890.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny27.1KShares$28,4550.0% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $8.67M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...